Göttlicher Group
Research Group Small Molecule Modulators of Intermediary Metabolism
Our research aims at identifying novel targets for small molecules that could modulate intermediary metabolism in order to control body weight or pathologies associated with metabolic disorders such as metabolic syndrome, steatosis hepatis or diabetes.
About our Research
Our research starts from two complementary phenotypes:
One is the observation that mice deficient in histone deacetylase 2 – although expecting a normal life time – maintain a reduced body weight throughout life time.
The other phenotype is the improvement of insulin sensitivity in obese mice by a yet undisclosed small molecule which according to current data modulates an intracellular target protein. Our research is directed towards identifying and understanding the molecular machines underlying these phenotypes with the prospective for a rationally-guided and structural biology-aided development and improvement of small molecule modulators of metabolic disorders.
Our Publications
O'Neill, T.J. ; Seeholzer, T. ; Gewies, A. ; Gehring, T. ; Giesert, F. ; Hamp, I. ; Grass, C. ; Schmidt, H. ; Kriegsmann, K. ; Tofaute, M.J. ; Demski, K. ; Poth, T. ; Rosenbaum, M. ; Schnalzger, T. ; Ruland, J. ; Göttlicher, M. ; Kriegsmann, M. ; Naumann, R. ; Heissmeyer, V. ; Wurst, W. ; Krappmann, D.
TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease.Göttlicher, M. ; Sattler, M. ; Brönstrup, M.
New frontiers in drug discovery: Academia meets industry at the International Helmholtz Drug Discovery Conference (HDDC).Contact
